- Imara Inc (NASDAQ:IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
- In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments.
- In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion.
- In April, Imara posted interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.
- No meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.
- Imara announced discontinuing the Ardent and Forte trials and further developing tovinontrine in sickle cell disease and beta-thalassemia.
- Price Action: IMRA shares are up 37.60% at $1.61 during the premarket session on the last check Wednesday.
Apple Adjusts Legal Guidelines After Notification Data Concerns Pointed Out By Democratic Senator
Tech giant Apple has updated its guidelines to incorporate data from push notifications, saying it could be subject to legal requests.
